维多珠单抗在炎症性肠病中诱导或诱发关节炎和/或骶髂关节炎:病例系列
本文报告5例接受维多珠单抗治疗的炎症性肠病患者,在治疗后迅速出现新发或加重的骶髂关节炎或关节炎。结论认为维多珠单抗似乎对关节炎/骶髂关节炎无效,甚至可能诱导其发生,但需更大队列研究提供患病率、演变和机制信息。
要点
- 维多珠单抗治疗炎症性肠病后,5例患者迅速出现新发或加重的骶髂关节炎或关节炎。
- 维多珠单抗似乎对关节炎/骶髂关节炎无疗效,甚至可能诱导其发生。
- 需更大队列研究明确患病率、演变及机制。
核心结论
- 维多珠单抗治疗似乎对关节炎和/或骶髂关节炎无疗效,甚至可能诱导其发生。
研究设计与样本
- 病例系列报告了5例接受维多珠单抗治疗的炎症性肠病患者。
主要发现
- 5例炎症性肠病患者在接受维多珠单抗治疗后迅速出现新发或加重的骶髂关节炎或关节炎。
临床怎么用
- 对接受维多珠单抗治疗的炎症性肠病患者,应警惕新发或加重的关节炎和/或骶髂关节炎。
局限性
- 病例系列样本量小,需更大队列研究提供患病率、演变和机制信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to α4β7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect of vedolizumab could be expected based on the restricted presence of the α4β7-mucosal vascular addressin cell adhesion molecule 1 complex in the gut, past combined success with anti-tumour necrosis factor, and previous demonstration of α4β7 integrin in the joint, led to the expectation of a therapeutic efficacy in spondyloarthritis. Nonetheless, the effect of vedolizumab on extraintestinal manifestations-and especially the joint-has not been reported so far. CASE REPORT: A series of five patients with IBD who were treated with vedolizumab and promptly developed new onset or exacerbation of sacroiliitis or arthritis are reported. CONCLUSIONS: Vedolizumab therapy does not seem to show any efficacy in and might even induce arthritis and/or sacroiliitis. However, larger cohort studies are needed to provide information on the prevalence, the evolution and underlying mechanism.
引用
- Varkas G, Thevissen K, De Brabanter G, et al. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis. 2016. PMID: 27899374. doi:10.1136/annrheumdis-2016-210233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。